Understanding the trajectory of nontuberculous mycobacterial pulmonary disease (#NTMPD) demands comprehensive longitudinal data. This study aims to establish three cohorts, providing insights into disease progression and treatment outcomes over a period of 24 months.

There is currently an unmet need for new #NTMPD treatments. Check out this paper co-authored by our CMO Dr. Kamal Hamed titled "Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720" discussing the challenges in managing NTM-PD: brnw.ch/21wHYsc

Would you like to join a growing network of over 500 healthcare professionals and researchers representing more than 200 different centres in the UK? Click here for more information and to join us! ntmnetworkuk.com/join-the-netwo… #NTM #respiratory #NTMdisease #NTMPD #NTMlungdisease

Our team came dressed to impress on #RareDiseaseDay! Along with sharing our colors and lighting up our windows, Sperobes attended a Lunch & Learn with Kenneth N. Olivier, MD, MPH, of @UNC_SOM on pulmonary NTM lung infections. #LightUpForRare #ShareYourColors #NTMPD

Our lead candidate has the potential to be the first approved of its kind in #NTMPD. We’re developing a novel oral agent to potentially arrest NTM infection and prevent lung damage caused by infection. Visit our website to learn more about our pipeline: sperotherapeutics.com/patients/spr-7…

As our team strives to bring differentiated therapeutics to those with #NTMPD, @NTMinfo is an online patient resource that provides insight into this rare #InfectiousDisease, information on support groups, and relevant organizations. Discover more here: brnw.ch/21wGo5S

As 2023 comes to a close, we're looking ahead to unfolding opportunities. In 2024, we're positioned to continue advancing our pipeline, focusing on incubating hope for patients with #InfectiousDiseases, including #MDR #BacterialInfections & nontuberculous mycobacterial (#NTMPD).

Spero’s mission is to bring hope to patients living with #InfectiousDiseases & #RareDiseases. Our lead candidate has the potential to be the first novel oral antibiotic approved for the first-line treatment of #NTMPD, a rare #OrphanDisease. Learn more: sperotherapeutics.com/pipeline/spero…

To further our commitment to increasing #NTMPD awareness, we asked Robert Salata, MD, FACP, FIDSA, about the current challenges around treating and managing #InfectiousDiseases like this rare #PulmonaryDisease. Visit our website to continue watching: brnw.ch/21wE14F

#DYK the elderly & those with compromised immune or lung function are at the greatest risk of nontuberculous mycobacterial (NTM) infections, leading to #InfectiousDiseases like #NTMPD, a rare #PulmonaryDisease. Read about it & the future of treatment: brnw.ch/21wDOj5

As we continue to increase NTM awareness, Patrick Flume, MD of MUSC Health, shares insights on managing #NTMPD in cystic fibrosis patients including routine screening and #AntimicrobialResistance. Check out the video on our website to continue watching: brnw.ch/21wDFLM

As part of our effort to bring awareness of the growing global health concern around #NTMPD, we asked Kenneth Olivier, MD, MPH, Professor of Medicine Director at UNC, about the cause and emergence of a rare #InfectiousDisease like NTMPD. Watch chapter 1: sperotherapeutics.com/#physician-vid…

As part of our effort to bring awareness of the growing global health concern around #NTMPD, we asked HCPs in the space to explain key aspects for this rare #InfectiousDisease. The more we know, the greater our strength. Watch the insightful discussions: fal.cn/3ADW0

Yesterday, we announced our fourth quarter and full year 2022 operating results, including updated progress on our mission to find potential therapeutic solutions for #NTMPD and for #cUTI alongside our partner @GSK. Click here for details: bit.ly/3K1v5zf

Spero is answering the call for effective, well-tolerated therapies for #NTMPD & #MDR #BacterialInfections with an audacious mission to find new answers & new treatment approaches to combat #RareDiseases for future generations. Learn about our solutions: bit.ly/3v2Ldtj

#RareDiseaseDay is dedicated to discussing improving healthcare for those living with a #RareDisease. Reflecting on the challenges affected individuals face, we're proud to highlight our patient-focused approach as we develop a potential therapy for #NTMPD. Hope is in our name.

What is NTM pulmonary disease (#NTMPD)? It’s a lung infection caused by a group of bacteria called nontuberculous mycobacteria. It can be difficult to diagnose and treat. Sperobes are dedicated to developing potential treatments to help patients breathe a little easier.

#ICYMI our President & CEO, @AMahadevia, led a fireside chat at the 5th Annual Evercore ISI #HealthCONx Conference. He provided insight into our lead candidate's novel MOA, our GSK partnership, & unmet needs of those affected by #cUTI & #NTMPD. Watch here: bit.ly/3jtb4bd

We’re excited to host a virtual R&D Event today at 11:30 am on #NTMPD and our SPR720 development program, a potential novel first-line oral therapy for #NTM infections. An #NTM KOL will present and @NTMinfo will discuss the patient journey. Register here: bit.ly/3yfuJQA